Show simple item record

dc.creatorStanković, Sanja
dc.creatorAšanin, Milika
dc.creatorTrifunović, Danijela
dc.creatorMajkić-Singh, Nada
dc.creatorMiljković, Aleksandar
dc.creatorIgnjatović, Svetlana
dc.creatorMrdović, Igor
dc.creatorMatić, Dragan
dc.creatorSavić, Lidija
dc.creatorOstojić, Miodrag
dc.creatorVasiljević, Zorana
dc.description.abstractBackground: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt 463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p lt 0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)en
dc.publisherClin Lab Publ, Heidelberg
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS//
dc.sourceClinical Laboratory
dc.subjectLipoprotein-associated phospholipase A(2)en
dc.subjectprimary percutaneous coronary interventionen
dc.titleUtility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Interventionen
dcterms.abstractМатић, Драган; Остојић, Миодраг; Савић, Лидија; Васиљевић, Зорана; Трифуновић, Данијела; Мрдовић, Игор; Миљковић, Aлександар; Aшанин, Милика; Станковић, Сања; Мајкић-Сингх, Нада; Игњатовић, Светлана;
dc.citation.other58(11-12): 1135-1144

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record